Transaction · 0000950170-25-032708

Robb Gary Charles

Robb Gary Charles, CBO, reported a transaction classified as withholding at CORCEPT THERAPEUTICS INC involving 250.000000 shares for an estimated $15145.00. Reported holdings after the transaction were 22906.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

withholdingSEC transaction code FCBO
CORTCORCEPT THERAPEUTICS INC
Filing timeMar 05
Trade dateMar 03, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2025-03-05Filed 548 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
withholding
Code F
Identifier
0000950170-25-032708
Common Stock
Transaction date
Mar 03, 2025
Filed Mar 05, 2025, 12:27 AM · 2d delay
Shares
250 sh
$6.05k per share
Estimated value
-$1.51M
Computed from shares × price
Holdings after
22.9k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Business Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

  2. F2

    The closing price on February 28, 2025 was used to calculate the withholding obligation.

  3. F3

    Includes 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024, 503 shares underlying unvested restricted stock awards granted to the R…

  4. F4

    The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…

  5. F5

    In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

  6. F6

    Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…

  7. F7

    These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

  8. F8

    Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Original filing · 0000950170-25-032708
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT